

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006

L1 7010 S TESTIS (W) SPECIFIC  
L2 431 S TYROSINE (W) LIGASE?  
L3 3 S L1 AND L2  
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)  
L5 405 S TUBULIN (A) L2  
L6 7556238 S CLON? OR EXPRESS? OR RECOMBINANT  
L7 83 S L5 AND L6  
L8 39 DUP REM L7 (44 DUPLICATES REMOVED)  
L9 8 S L8 AND TESTIS  
E FEDER J N/AU  
L10 185 S E3  
E WU S/AU  
L11 3568 S E3  
E NELSON T C/AU  
L12 130 S E3  
L13 3853 S L10 OR L11 OR L12  
L14 1 S L2 AND L13

=

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the  
IPC reform  
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 16 FEB 22 Status of current WO (PCT) information on STN  
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

=> file medline embase biosis biotechds scisearch hcaplus ntis lifesci  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:09:07 ON 28 FEB 2006

FILE 'EMBASE' ENTERED AT 12:09:07 ON 28 FEB 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:09:07 ON 28 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 12:09:07 ON 28 FEB 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 12:09:07 ON 28 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 12:09:07 ON 28 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 12:09:07 ON 28 FEB 2006  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2006)

FILE 'LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006  
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

=> s testis (w) specific  
L1 7010 TESTIS (W) SPECIFIC

=> s tyrosine (w)ligase?  
L2 431 TYROSINE (W) LIGASE?

=> s l1 and l2  
L3 3 L1 AND L2

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)

=> d 1-2 ibib ab

L4 ANSWER 1 OF 2 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN  
DUPLICATE 1

ACCESSION NUMBER: 2004-07314 BIOTECHDS

TITLE: New testis-specific tubulin  
tyrosine-ligase-like BGS-42 polypeptide,  
useful for preventing, treating or ameliorating a medical  
condition, e.g. aberrant cellular proliferation, reproductive  
disorders or testicular disorders;  
involving vector-mediated gene transfer, expression in  
host cell for use in gene therapy

AUTHOR: FEDER J N; WU S; NELSON T C  
PATENT ASSIGNEE: BRISTOL-MYERS SQUIBB CO  
PATENT INFO: WO 2004005487 15 Jan 2004  
APPLICATION INFO: WO 2003-US21605 9 Jul 2003  
PRIORITY INFO: US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: WPI: 2004-099381 [10]

AB DERWENT ABSTRACT:

NOVELTY - A testis-specific tubulin tyrosine  
-ligase-like polypeptide, designated BGS-42 polypeptide, is  
new.

DETAILED DESCRIPTION - A testis-specific tubulin  
tyrosine-ligase-like polypeptide, designated BGS-42  
polypeptide comprises or consists of: (a) a polypeptide fragment, domain,  
epitope or the full-length protein of a fully defined sequence of 541  
amino acids (I), as given in the specification, or the encoded sequence  
included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase  
activity; (b) a polypeptide comprising amino acids 2-541 of the sequence  
of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus  
the start methionine; (c) a polypeptide comprising amino acids 1-541 or  
73-365 of the sequence of (I); or (d) a polypeptide comprising at least  
424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are  
also included for: (1) an isolated nucleic acid molecule comprising or  
consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully  
defined in the specification, or a polynucleotide fragment of the cDNA  
sequence included in ATCC Deposit Number PTA-4454, which is hybridizable  
to the sequence of (II); (b) a polynucleotide encoding a polypeptide  
fragment, domain, epitope or the full-length protein of the sequence of  
(I), or a polypeptide fragment, domain or epitope encoded by the cDNA  
sequence included in ATCC Deposit Number PTA-4454, which is hybridizable  
to the sequence of (II), having tyrosine tubulin ligase activity; (c) a  
polynucleotide which is a variant or an allelic variant of (II); (d)  
nucleotides 156-1775 of the sequence of (II), where the nucleotides  
encode a polypeptide corresponding to amino acids 2-541 of (I) minus the  
start methionine; (e) nucleotides 153-1775 of the sequence of (II), where  
the nucleotides encode a polypeptide corresponding to amino acids 1-541  
of (I) including the start codon; (f) nucleotides 369-1247 of the  
sequence of (II), where the nucleotides encode a polypeptide  
corresponding to amino acids 73-365 of (I); (g) a polynucleotide that  
encodes at least 424 contiguous amino acids of (I); (h) at least 1272  
contiguous nucleotides of (II); (i) a polynucleotide which represents the  
complementary sequence (antisense) of (II); (j) a polynucleotide capable  
of hybridizing under stringent conditions to any one of the  
polynucleotides above, where the polynucleotide does not hybridize under  
stringent conditions to a nucleic acid molecule having a nucleotide  
sequence of only A or only T residues; (k) a polynucleotide comprising or  
consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide  
sequence of 2241 bp, fully defined in the specification; (2) a  
recombinant vector comprising the isolated nucleic acid molecule; (3) an  
isolated antibody that binds specifically to BGS-42 polypeptide; (4) a  
recombinant host cell comprising the vector sequences, or expressing the  
BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing,  
treating or ameliorating a medical condition; and (7) diagnosing a  
pathological condition or a susceptibility to a pathological condition in  
a subject.

WIDER DISCLOSURE - Also disclosed are screening methods for  
identifying agonists and antagonists of the polynucleotides and  
polypeptides, and methods of controlling the expression of the  
polypeptide.

BIOTECHNOLOGY - Preparation (claimed): The BGS-42 polypeptide is  
prepared by standard recombinant methods. Making an isolated polypeptide  
comprises culturing the recombinant host cell under conditions such that  
the polypeptide is expressed, and recovering the polypeptide. Preferred

**Polypeptide:** The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

**ACTIVITY** - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

**MECHANISM OF ACTION** - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

**USE** - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

**ADMINISTRATION** - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

**EXAMPLE** - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene expression. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

DOCUMENT NUMBER: 141:238811  
 TITLE: Protein and cDNA sequences of a novel human  
 testis-specific tubulin  
 tyrosine ligase like protein BGS-42,  
 and diagnostic and therapeutic use  
 INVENTOR(S): Feder, John N.; Nelson, Thomas C.; Wu, Shujian;  
 Krystek, Stanley R.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 199 pp., Cont.-in-part of U.S.  
 Ser. No. 615,659.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004171131	A1	20040902	US 2003-635977	20030807
US 2004157234	A1	20040812	US 2003-615659	20030709
PRIORITY APPLN. INFO.:			US 2002-394725P	P 20020709
			US 2003-615659	A2 20030709

AB The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006

L1 7010 S TESTIS (W) SPECIFIC  
 L2 431 S TYROSINE (W) LIGASE?  
 L3 3 S L1 AND L2  
 L4 2 DUP REM L3 (1 DUPLICATE REMOVED)

=> s tubulin (a) l2

L5 405 TUBULIN (A) L2

=> s clon? or express? or recombinant

L6 7556238 CLON? OR EXPRESS? OR RECOMBINANT

=> s l5 and l6

L7 83 L5 AND L6

=> dup rem l7

PROCESSING COMPLETED FOR L7

L8 39 DUP REM L7 (44 DUPLICATES REMOVED)

=> d 1-39 ibib ab

L8 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:156228 HCAPLUS  
 Correction of: 2005:16967

DOCUMENT NUMBER: 142:192331  
 Correction of: 142:108390

TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812782	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. **expression** of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L8 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1311496 HCAPLUS

DOCUMENT NUMBER: 144:49649

TITLE: Association of gene **expression** profiles with asthma in peripheral blood cells

INVENTOR(S): Kachalsky, Sylvia G.; Horev, Guy

PATENT ASSIGNEE(S): Linkagene Ltd., Israel

SOURCE: PCT Int. Appl., 74 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118403	A2	20051215	WO 2005-IL590	20050605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-576599P P 20040604

AB The present invention relates to methods of identifying biomarkers for disease, which comprise measuring gene **expression** levels in subpopulations of blood cells obtained from subjects of closed populations. Particularly, the present invention relates to methods of diagnosing, monitoring and prognosing diseases comprising determining **expression** levels of disease-specific genes. Thus, a library of about 41,500 cDNA clones derived from the I.M.A.G.E consortium was printed in microarrays comprising the whole transcriptome and used to screen RNA isolated from leukocytes from a Cochin Jewish population known as susceptible to high occurrences of asthma. Comparison of **expression** profiles from asthma and non-asthma individuals identified 783 biomarker transcripts for asthma.

L8 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2005:984082 HCAPLUS

DOCUMENT NUMBER: 143:280551

TITLE: Human glucocorticoid receptor coactivator STAMP modulating glucocorticoid-responsive gene **expression**, its orangutan and green monkey homolog, and therapeutic use thereof

INVENTOR(S): Simons, S. Stoney, Jr.; He, Yuanzheng

PATENT ASSIGNEE(S): Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082935	A1	20050909	WO 2005-US6393	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-548039P P 20040226

AB The invention provides a new glucocorticoid receptor (GR) coactivator named STAMP (SRC-1 and TIF2 Associated Modulatory Protein) that can modulate transcription of glucocorticoid-responsive genes. The isolated STAMP gene is located on chromosome 14q24.3 and contains 32 introns, and its encodes a 1277 amino acid protein (predominant form, with predicted mol. weight of 143 kDa) or a 1281 amino acid protein with four extra amino acid at



N-terminus. Activity of STAMP in GR-mediated induction. STAMP and TIF2 act cooperatively to modulate glucocorticoid receptor activity and STAMP activity requires the RID (receptor interaction domain) domains (around residues 834-1277) that mediate TIF2 binding to GR and/or STAMP. Also provided are siRNAs shown to inhibit STAMP actions. The invention also provides antibodies that can bind STAMP and modulate its activity. In addition, the invention provides antisense, ribozyme and siRNA STAMP nucleic acids that can modulate the expression of STAMP. Also provided are compns. and methods for modulating glucocorticoid-responsive gene expression and for treating a variety of diseases and conditions.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:497356 HCAPLUS

DOCUMENT NUMBER: 143:39118

TITLE: Gene expression profiling for diagnosis, prognosis, and therapy of osteoarthritis and other diseases using microarrays

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 157 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004037841	A1	20040226	US 2002-85783	20020228
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004248169	A1	20041209	US 2004-812737	20040330
WO 2004112589	A2	20041229	WO 2004-US20836	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-115125P P 19990106  
US 2000-477148 B1 20000104  
US 2001-271955P P 20010228  
US 2001-275017P P 20010312  
US 2001-305340P P 20010713  
US 2002-85783 A2 20020228  
US 2002-268730 A2 20021009  
US 2003-601518 A2 20030620  
US 2004-802875 A2 20040312  
US 2004-809675 A 20040325

AB The present invention relates to gene **expression** profiling for diagnosis, prognosis and therapy of osteoarthritis and other diseases using microarray methods. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L8 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:325595 HCAPLUS

DOCUMENT NUMBER: 142:353388

TITLE: Gene **expression** profiles and biomarkers for the detection of Alzheimer's disease-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): ChondroGene Ltd., Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005079514	A1	20050414	US 2004-812827	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Alzheimer's disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess

the effect of a particular treatment regimen.

L8 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160724 HCAPLUS  
DOCUMENT NUMBER: 142:259424  
TITLE: Gene **expression** profiles and biomarkers for  
the detection of asthma-related and other  
disease-related gene transcripts in blood  
INVENTOR(S): Liew, Choong-Chin  
PATENT ASSIGNEE(S): Chondrogene Limited, Can.  
SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S.  
Ser. No. 802,875.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 47  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2005042630	A1	20050224	US 2004-816357	20040401
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-816357	A 20040401

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular asthma, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L8 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:499078 HCAPLUS  
DOCUMENT NUMBER: 143:23514  
TITLE: A vital role of **tubulin-tyrosine-ligase** for neuronal organization  
AUTHOR(S): Erck, Christian; Peris, Leticia; Andrieux, Annie;  
Meissirel, Claire; Gruber, Achim D.; Vernet, Muriel;  
Schweitzer, Annie; Saoudi, Yasmina; Pointu, Herve;  
Bosc, Christophe; Salin, Paul A.; Job, Didier;

CORPORATE SOURCE: Wehland, Juergen  
Department of Cell Biology, German Research Center for  
Biotechnology, Braunschweig, D-38124, Germany  
SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America (2005), 102(22), 7853-7858  
CODEN: PNASA6; ISSN: 0027-8424  
PUBLISHER: National Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Tubulin is subject to a special cycle of de tyrosination/tyrosination in which the C-terminal tyrosine of  $\alpha$ -tubulin is cyclically removed by a carboxypeptidase and readded by a tubulin-tyrosine-ligase (TTL). This tyrosination cycle is conserved in evolution, yet its physiol. importance is unknown. Here, we find that TTL suppression in mice causes perinatal death. A minor pool of tyrosinated (Tyr-)tubulin persists in TTL null tissues, being present mainly in dividing TTL null cells where it originates from tubulin synthesis, but it is lacking in postmitotic TTL null cells such as neurons, which is apparently deleterious because early death in TTL null mice is, at least in part, accounted for by a disorganization of neuronal networks, including a disruption of the cortico-thalamic loop. Correlatively, cultured TTL null neurons display morphogenetic anomalies including an accelerated and erratic time course of neurite outgrowth and a premature axonal differentiation. These anomalies may involve a mislocalization of CLIP170, which we find lacking in neurite extensions and growth cones of TTL null neurons. Our results demonstrate a vital role of TTL for neuronal organization and suggest a requirement of Tyr-tubulin for proper control of neurite extensions.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 39 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:276126 SCISEARCH

THE GENUINE ARTICLE: 902DT

TITLE: Global effects of BCR/ABL and TEL/PDGFR beta expression on the proteome and phosphoproteome - Identification of the rho pathway as a target of BCR/ABL  
AUTHOR: Unwin R D; Sternberg D W; Lu Y N; Pierce A; Gilliland D G; Whetton A D (Reprint)

CORPORATE SOURCE: Univ Manchester, Christie Hosp, Fac Med & Human Sci, Manchester M20 9BX, Lancs, England (Reprint); Univ Manchester, Fac Med & Human Sci, Manchester M20 9BX, Lancs, England; Christie Hosp, Paterson Inst Canc Res, Inst Mass Spectrometry, Manchester M20 9BX, Lancs, England; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Mt Sinai Sch Med, New York, NY 10029 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA  
awhetton@picr.man.ac.uk

COUNTRY OF AUTHOR: England; USA

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (25 FEB 2005) Vol. 280, No. 8, pp. 6316-6326.  
ISSN: 0021-9258.

PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 80

ENTRY DATE: Entered STN: 18 Mar 2005

Last Updated on STN: 18 Mar 2005

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Many leukemic oncogenes form as a consequence of gene fusions or mutation that result in the activation or overexpression of a tyrosine

kinase. To identify commonalities and differences in the action of two such kinases, breakpoint cluster region (BCR)/ABL and TEL/PDGFRbeta, two-dimensional gel electrophoresis was employed to characterize their effects on the proteome. While both oncogenes affected expression of specific proteins, few common effects were observed. A number of proteins whose expression is altered by BCR/ABL, including gelsolin and stathmin, are related to cytoskeletal function whereas no such changes were seen in TEL/PDGFRbeta-transfected cells. Treatment of cells with the kinase inhibitor STI571 for 4-h reversed changes in expression of some of these cytoskeletal proteins. Correspondingly, BCR/ABL-transfected cells were less responsive to chemotactic and chemokinetic stimuli than non-transfected cells and TEL/PDGFRbeta-transfected Ba/F3 cells. Decreased motile response was reversed by a 16-h treatment with STI571. A phosphoprotein-specific gel stain was used to identify TEL/PDGFRbeta and BCR/ABL-mediated changes in the phosphoproteome. These included changes on Crkl, Ras-GAP-binding protein 1, and for BCR/ABL, cytoskeletal proteins such as tubulin, and Nedd5. Decreased phosphorylation of Rho-GTPase dissociation inhibitor (Rho GDI) was also observed in BCR/ABL-transfected cells. This results in the activation of the Rho pathway, and treatment of cells with Y27632, an inhibitor of Rho kinase, inhibited DNA synthesis in BCR/ABL-transfected Ba/F3 cells but not TEL/PDGFRB-expressing cells. Expression of a dominant-negative RhoA inhibited both DNA synthesis and transwell migration, demonstrating the significance of this pathway in BCR/ABL-mediated transformation.

L8 ANSWER 9 OF 39 MEDLINE on STN  
 ACCESSION NUMBER: 2005313865 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 15890843  
 TITLE: Tubulin polyglutamylase enzymes are members of the TTL domain protein family.  
 AUTHOR: Janke Carsten; Rogowski Krzysztof; Wloga Dorota; Regnard Catherine; Kajava Andrey V; Strub Jean-Marc; Temurak Nevzat; van Dijk Juliette; Boucher Dominique; van Dorsselaer Alain; Suryavanshi Swati; Gaertig Jacek; Edde Bernard  
 CORPORATE SOURCE: Centre de Recherches de Biochimie Macromoléculaire, CNRS, 34293 Montpellier, France.  
 SOURCE: Science, (2005 Jun 17) Vol. 308, No. 5729, pp. 1758-62. Electronic Publication: 2005-05-12. Journal code: 0404511. E-ISSN: 1095-9203.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200506  
 ENTRY DATE: Entered STN: 20050618  
 Last Updated on STN: 20050701  
 Entered Medline: 20050630  
 AB Polyglutamylation of tubulin has been implicated in several functions of microtubules, but the identification of the responsible enzyme(s) has been challenging. We found that the neuronal tubulin polyglutamylase is a protein complex containing a tubulin tyrosine ligase-like (TLL) protein, TLL1. TLL1 is a member of a large family of proteins with a TTL homology domain, whose members could catalyze ligations of diverse amino acids to tubulins or other substrates. In the model protist Tetrahymena thermophila, two conserved types of polyglutamylases were characterized that differ in substrate preference and subcellular localization.

L8 ANSWER 10 OF 39 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2005:412589 SCISEARCH  
 THE GENUINE ARTICLE: 914YX

TITLE: 3-Nitrotyrosine attenuates respiratory syncytial virus infection in human bronchial epithelial cell line  
AUTHOR: Huang Y C T (Reprint); Li Z W; Brighton L E; Carson J L; Becker S; Soukup J M  
CORPORATE SOURCE: CB 7315, 104 Mason Farm Rd, Chapel Hill, NC 27599 USA (Reprint); US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA  
huang.tony@epa.gov  
COUNTRY OF AUTHOR: USA  
SOURCE: AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (MAY 2005) Vol. 288, No. 5, pp. L988-L996.  
ISSN: 1040-0605.  
PUBLISHER: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.  
DOCUMENT TYPE: Article; Journal  
LANGUAGE: English  
REFERENCE COUNT: 55  
ENTRY DATE: Entered STN: 28 Apr 2005  
Last Updated on STN: 28 Apr 2005

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB 3-Nitrotyrosine (NO<sub>2</sub>Tyr), an L-tyrosine derivative during nitrative stress, can substitute the COOH-terminal tyrosine of alpha-tubulin, posttranslationally altering microtubular functions. Because infection of the cells by respiratory syncytial virus (RSV) may require intact microtubules, we tested the hypothesis that NO<sub>2</sub>Tyr would inhibit RSV infection and intracellular signaling via nitrotyrosination of alpha-tubulin. A human bronchial epithelial cell line (BEAS-2B) was incubated with RSV with or without NO<sub>2</sub>Tyr. The release of chemokines and viral particles and activation of interferon regulatory factor-3 (IRF-3) were measured. Incubation with NO<sub>2</sub>Tyr increased nitrotyrosinated alpha-tubulin, and NO<sub>2</sub>Tyr colocalized with microtubules. RSV-infected cells released viral particles, RANTES, and IL-8 in a time- and dose-dependent manner, and intracellular RSV proteins coprecipitated with alpha-tubulin. NO<sub>2</sub>Tyr attenuated the RSV- induced release of RANTES, IL-8, and viral particles by 50-90% and decreased alpha-tubulin-associated RSV proteins. 3-Chlorotyrosine, another L-tyrosine derivative, had no effects. NO<sub>2</sub>Tyr also inhibited the RSV- induced shift of the unphosphorylated form I of IRF-3 to the phosphorylated form II. Pre-exposure of the cells to NO<sub>2</sub> (0.15 ppm, 4 h), which produced diffuse protein tyrosine nitration, did not affect RSV- induced release of RANTES, IL-8, or viral particles. NO<sub>2</sub>Tyr did not affect the potential of viral spreading to the neighboring cells since the RSV titers were not decreased when the uninfected cells were cocultured with the preinfected cells in NO<sub>2</sub>Tyr-containing medium. These results indicate that NO<sub>2</sub>Tyr, by replacing the COOH-terminal tyrosine of alpha-tubulin, attenuated RSV infection, and the inhibition appeared to occur at the early stages of RSV infection.

L8 ANSWER 11 OF 39 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN  
DUPLICATE 2

ACCESSION NUMBER: 2004-07314 BIOTECHDS

TITLE: New testis-specific tubulin tyrosine-ligase-like BGS-42 polypeptide, useful for preventing, treating or ameliorating a medical condition, e.g. aberrant cellular proliferation, reproductive disorders or testicular disorders; involving vector-mediated gene transfer, expression in host cell for use in gene therapy

AUTHOR: FEDER J N; WU S; NELSON T C  
PATENT ASSIGNEE: BRISTOL-MYERS SQUIBB CO  
PATENT INFO: WO 2004005487 15 Jan 2004  
APPLICATION INFO: WO 2003-US21605 9 Jul 2003

PRIORITY INFO: US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: WPI: 2004-099381 [10]

AB DERWENT ABSTRACT:

NOVELTY - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide, is new.

DETAILED DESCRIPTION - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide comprises or consists of: (a) a polypeptide fragment, domain, epitope or the full-length protein of a fully defined sequence of 541 amino acids (I), as given in the specification, or the encoded sequence included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase activity; (b) a polypeptide comprising amino acids 2-541 of the sequence of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus the start methionine; (c) a polypeptide comprising amino acids 1-541 or 73-365 of the sequence of (I); or (d) a polypeptide comprising at least 424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

WIDER DISCLOSURE - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

BIOTECHNOLOGY - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical

condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of **expression** of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of **expression** of the polypeptide.

ACTIVITY - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene **expression**. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

L8 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3  
ACCESSION NUMBER: 2005:156681 HCAPLUS  
Correction of: 2005:60757  
DOCUMENT NUMBER: 142:216629  
Correction of: 142:132329  
TITLE: Gene **expression** profiles and biomarkers for



the detection of hyperlipidemia and other  
disease-related gene transcripts in blood  
INVENTOR(S): Liew, Choong-Chin  
PATENT ASSIGNEE(S): Chondrogene Limited, Can.  
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S.  
Ser. No. 802,875.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 47  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812777	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L8 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:824055 HCAPLUS  
DOCUMENT NUMBER: 141:330185  
TITLE: Gene expression profiling for diagnosis and treatment of angiogenesis-related disorders  
INVENTOR(S): Gonda, Thomas John; Kremmidiotis, Gabriel  
PATENT ASSIGNEE(S): Bionomics Limited, Australia  
SOURCE: PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085675	A1	20041007	WO 2004-AU383	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1608778 A1 20051228 EP 2004-723453 20040326

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: AU 2003-901511 A 20030328  
 WO 2004-AU383 W 20040326

AB The present invention provides methods of gene **expression** profiling for diagnosis and treatment of angiogenesis-related disorders. Diseases of the invention include cancer, rheumatoid arthritis, diabetic retinopathy, psoriasis, cardiovascular diseases such as atherosclerosis, ischemic limb disease and coronary heart disease.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1997 HCAPLUS

DOCUMENT NUMBER: 142:111841

TITLE: Gene **expression** profiles and biomarkers for the detection of depression-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330

PRIORITY APPLN. INFO.: US 1999-115125P P 19990106  
 US 2000-477148 B1 20000104  
 US 2002-268730 A2 20021009  
 US 2003-601518 A2 20030620  
 US 2004-802875 A2 20040312  
 US 2004-812702 A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular mental depression, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy,

systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L8 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:60760 HCAPLUS

Correction of: 2004:1036573

DOCUMENT NUMBER: 142:153477

Correction of: 142:16776

TITLE: Gene **expression** profiles and biomarkers for the detection of Chagas disease and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-813097	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Chagas disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L8 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:60759 HCAPLUS  
 Correction of: 2004:1036572  
 DOCUMENT NUMBER: 142:111840  
 Correction of: 142:16824  
 TITLE: Gene **expression** profiles and biomarkers for  
 the detection of lung disease-related and other  
 disease-related gene transcripts in blood  
 INVENTOR(S): Liew, Choong-Chin  
 PATENT ASSIGNEE(S): Chondrogene Limited, Can.  
 SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S.  
 Ser. No. 802,875.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 47  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812764	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L8 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:60754 HCAPLUS  
 Correction of: 2004:1036571  
 DOCUMENT NUMBER: 142:233342  
 Correction of: 142:16836  
 TITLE: Sequences of human schizophrenia related genes and use  
 for diagnosis, prognosis and therapy  
 INVENTOR(S): Liew, Choong-Chin  
 PATENT ASSIGNEE(S): Chondrogene Limited, Can.  
 SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S.  
 Ser. No. 802,875.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 47  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005208519	A1	20050922	US 2004-989191	20041115
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812731	A 20040330
			WO 2004-US20836	A2 20040621

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L8 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:60755 HCAPLUS  
Correction of: 2004:1036570

DOCUMENT NUMBER: 142:154259  
Correction of: 142:36938

TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318

US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812707	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L8 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:722839 HCAPLUS

DOCUMENT NUMBER: 141:238811

TITLE: Protein and cDNA sequences of a novel human testis-specific tubulin tyrosine ligase like protein BGS-42, and diagnostic and therapeutic use

INVENTOR(S): Feder, John N.; Nelson, Thomas C.; Wu, Shujian; Krystek, Stanley R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 199 pp., Cont.-in-part of U.S. Ser. No. 615,659.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004171131	A1	20040902	US 2003-635977	20030807
US 2004157234	A1	20040812	US 2003-615659	20030709
PRIORITY APPLN. INFO.:			US 2002-394725P	P 20020709
			US 2003-615659	A2 20030709

AB The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and **recombinant** and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L8 ANSWER 20 OF 39 MEDLINE on STN

DUPLICATE 4

ACCESSION NUMBER: 2004470309 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 15382060  
 TITLE: Low **expression** of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis.  
 AUTHOR: Kato Chiaki; Miyazaki Kou; Nakagawa Atsuko; Ohira Miki; Nakamura Yohko; Ozaki Toshinori; Imai Toshio; Nakagawara Akira  
 CORPORATE SOURCE: Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba, Japan.  
 SOURCE: International journal of cancer. Journal international du cancer, (2004 Nov 10) Vol. 112, No. 3, pp. 365-75. Journal code: 0042124. ISSN: 0020-7136.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200412  
 ENTRY DATE: Entered STN: 20040922  
 Last Updated on STN: 20041219  
 Entered Medline: 20041202

AB Neuroblastoma (NBL), one of the most common childhood solid tumors, has a distinct nature in different prognostic subgroups. However, the precise mechanism underlying this phenomenon remains largely unknown. To understand the molecular and genetic bases of neuroblastoma, we have generated its cDNA libraries and identified a human ortholog of tubulin tyrosine ligase gene (hTTL/Nbla0660) as a differentially **expressed** gene at high levels in a favorable subset of the tumor. Tubulin is subjected to several types of evolutionarily conserved posttranslational modification, including tyrosination and detyrosination. Tubulin tyrosine ligase catalyzes ligation of the tyrosine residue to the COOH terminus of the detyrosinated form of alpha-tubulin. The measurement of hTTL mRNA **expression** in 74 primary neuroblastomas by quantitative real-time reverse transcription-PCR revealed that its high **expression** was significantly associated with favorable stages (1, 2 and 4s;  $p = 0.0069$ ), high TrkA **expression** ( $p = 0.002$ ), a single copy of MYCN ( $p < 0.00005$ ), tumors found by mass screening ( $p = 0.0042$ ), nonadrenal origin ( $p = 0.0042$ ) and good prognosis ( $p = 0.023$ ). The log-rank test showed that high **expression** of hTTL was an indicator of favorable prognosis ( $p = 0.026$ ). Immunohistochemical analysis using specific antibodies generated by us demonstrated that tyrosinated tubulin (Tyr-tubulin), detyrosinated tubulin (Glu-tubulin) and hTTL as well as Delta2-tubulin were positive in favorable tumors, whereas only Delta2-tubulin was positive in the tumors with MYCN amplification. In an RTBM1 neuroblastoma cell line, hTTL was increased after treating the cells with bone morphogenetic protein 2 (BMP2) or all-trans retinoic acid (RA), which induced neuronal differentiation. These results suggest that the deregulated tubulin tyrosination/detyrosination cycle caused by decreased **expression** of hTTL is associated with inhibition of neuronal differentiation and enhancement of cell growth in the primary neuroblastomas with poor outcome.

L8 ANSWER 21 OF 39 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004018647 EMBASE  
 TITLE: Endophyte-Infected Tall Fescue Diet Alters Gene **Expression** in Heifer Luteal Tissue as Revealed by Interspecies Microarray Analysis.  
 AUTHOR: Jones K.L.; King S.S.; Iqbal M.J.  
 CORPORATE SOURCE: K.L. Jones, Dept. of Anim. Sci., Food and Nutr., S. Illinois University Carbondale, MC 4417, 1205 Lincoln

SOURCE: Drive, Carbondale, IL 62901, United States. kljones@siu.edu  
Molecular Reproduction and Development, (2004) Vol. 67, No.  
2, pp. 154-161. .  
Refs: 66  
ISSN: 1040-452X CODEN: MREDEE  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 004 Microbiology  
021 Developmental Biology and Teratology  
052 Toxicology  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 20040129  
Last Updated on STN: 20040129

AB Cattle consuming endophyte-infected tall fescue grass have an associated reduction in circulating progesterone and reduced reproductive rates. In this study, commercially available rat microarrays were used to analyze the gene expression in luteal tissues from heifers fed endophyte-free fescue, endophyte-infected fescue, or endophyte-infected fescue supplemented with the dopamine (DA) antagonist, domperidone. The number of hybridized spots represented approximately 40% of the total 10,000 rat genes/ESTs evaluated. Each luteal sample was analyzed in triplicate, resulting in within treatment correlation coefficients of  $\geq 0.98$ . Median values of mRNA abundance from luteal tissue taken from the endophyte-infected fed heifers revealed 598 genes and ESTs that were down regulated and 56 genes and ESTs that were upregulated compared with luteal mRNA values from the endophyte-free treatment. There were fewer comparative differences between median values from luteal mRNA from the endophyte-free versus feeding endophyte-infected plus domperidone treated heifers. Only 19 genes and ESTs were upregulated and two were down-regulated. .COPYRGT. 2004 Wiley-Liss, Inc.

L8 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:737915 HCAPLUS  
DOCUMENT NUMBER: 139:256359  
TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses  
INVENTOR(S): Zerhusen, Bryan D.; Patturajan, Meera; Kekuda, Ramesh; Miller, Charles E.; Rieger, Daniel K.; Pena, Carol E. A.; Shimkets, Richard A.; Li, Li; Berghs, Constance; Zhong, Mei; Casman, Stacie J.; Voss, Edward Z.; Boldog, Ferenc L.; Padigaru, Muralidhara; Smithson, Glennda; Shenoy, Suresh G.; Ji, Weizhen; Gorman, Linda; Vernet, Corine A. M.; Leite, Mario W.; Guo, Xiaojia; Anderson, David W.; Spytek, Kimberly A.; Gerlach, Valerie L.; Burgess, Catherine E.; Khrantsov, Nikolai V.; Ort, Tatiana; Ellerman, Karen; Rastelli, Luca; Agee, Michele L.; Chaudhuri, Amitabha; Chant, John S.; Dipippo, Vincent A.; Edinger, Shlomit; Eisen, Andrew; Gangolli, Esha A.; Giot, Loic; Ooi, Chean Eng; Rothenberg, Mark E.; Spaderna, Steven K.; Hjalt, Tord; Liu, Xiaohong; Taupier, Raymond J., Jr.; Catterton, Elina  
PATENT ASSIGNEE(S): Curagen Corporation, USA  
SOURCE: PCT Int. Appl., 562 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 159  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003076642	A2	20030918	WO 2002-US24459	20020802





pp. 47-53.

Journal code: 101142708. E-ISSN: 1424-859X.

PUB. COUNTRY: Switzerland  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200403  
ENTRY DATE: Entered STN: 20031023  
Last Updated on STN: 20040316  
Entered Medline: 20040315

AB **Tubulin tyrosine ligase (TTL)** is a cytosolic enzyme involved in the posttranslational modification of tubulin. In the assembled form microtubules are detyrosinated over time at the C-terminus of alpha-tubulin. After microtubular disassembly TTL restores tyrosine residues back to the detyrosinated tubulin leading to a cycle of detyrosination/tyrosination. Here we report the isolation of the human and mouse TTL cDNA. In comparison with other known TTL sequences, namely bovine, rat and porcine, we found that only porcine TTL deviates in length by having an insertion of two glutamate residues. In mouse and human TTL the genomic coding sequence is composed of seven exons with normal intron/exon boundaries. Using fluorescence in situ hybridization (FISH), we mapped the murine TTL gene to mouse chromosome 2 (MMU2). Human TTL has been located to chromosome 2q13 (HSA2q13). In addition, we found frequently truncated PCR products of hTTL transcripts with aberrant splicing in tumors.  
Copyright 2003 S. Karger AG, Basel

L8 ANSWER 24 OF 39 MEDLINE on STN DUPLICATE 6

ACCESSION NUMBER: 2003006942 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12512949

TITLE: Cloning of rat olfactory bulb tubulin tyrosine ligase cDNA: a dominant negative mutant and an antisense cDNA increase the proliferation rate of cells in culture.

AUTHOR: Mas Carlos R; Arregui Carlos O; Filiberti Adrian; Argarana Carlos E; Barra Hector S

CORPORATE SOURCE: Centro de Investigaciones en Quimica Biologica de Cordoba, CIQUIBIC (UNC-CONICET), Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, Argentina.

SOURCE: Neurochemical research, (2002 Nov) Vol. 27, No. 11, pp. 1453-8.

Journal code: 7613461. ISSN: 0364-3190.

PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200303  
ENTRY DATE: Entered STN: 20030107  
Last Updated on STN: 20030308  
Entered Medline: 20030307

AB In this paper we describe the cloning of rat olfactory bulb tubulin tyrosine ligase (TTL) cDNA, and investigate the physiological role of TTL in cultured CHO-K1 cells. Comparison of the deduced amino acid sequence of rat TTL cDNA with those of bovine and pig showed approximately 90% of identity. Transient transfection of CHO-K1 cells with a dominant negative mutant of TTL that contains the binding site to the substrate (tubulin) but not the catalytic domain, significantly decreased the endogenous TTL activity as determined in vitro. Similar results were obtained using a construction encoding for the antisense sequence of TTL. The reduction in TTL activity is not accompanied by a decrease in the tyrosination levels of microtubules, as judged by immunofluorescence analysis. Strikingly, the number of cells in the plates transfected with the mutant TTL or the antisense TTL cDNA was, after 72 h of culture, two and three times higher, respectively, than the

number of cells in the control plates. These results support the hypothesis that TTL may play a role in the regulation of the cell cycle in living cells.

L8 ANSWER 25 OF 39 MEDLINE on STN DUPLICATE .7  
ACCESSION NUMBER: 2001013397 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 11004583  
TITLE: Incorporation of nitrotyrosine into alpha-tubulin by recombinant mammalian tubulin-tyrosine ligase.  
AUTHOR: Kalisz H M; Erck C; Plessmann U; Wehland J  
CORPORATE SOURCE: Gesellschaft fur Biotechnologische Forschung, Abteilung Zellbiologie, Braunschweig, Germany.  
SOURCE: Biochimica et biophysica acta, (2000 Aug 31) Vol. 1481, No. 1, pp. 131-8.  
Journal code: 0217513. ISSN: 0006-3002.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200011  
ENTRY DATE: Entered STN: 20010322  
Last Updated on STN: 20010322  
Entered Medline: 20001102

AB Tubulin-tyrosine ligase (TTL, EC 6.3.2.25) from porcine brain, which catalyses the readdition of tyrosine to the C-terminus of dephosphorylated alpha-tubulin, was cloned and expressed in Escherichia coli as a glutathione S-transferase-fusion protein. Upon cleavage of the immobilised fusion protein, an electrophoretically homogeneous enzyme was obtained. Recombinant TTL, which exhibited similar catalytic properties as the mammalian enzyme purified from brain tissue, was capable of using nitrotyrosine as an alternative substrate in vitro. Incorporation of tyrosine into tubulin was competitively inhibited by nitrotyrosine with an apparent K(i) of 0.24 mM. The TTL-catalysed incorporation of nitrotyrosine as sole substrate into alpha-tubulin was clearly detectable at concentrations of 10 microM by immunological methods using nitrotyrosine specific antibodies. However, in competition with tyrosine 20-fold higher concentrations of nitrotyrosine were necessary before its incorporation became evident. Analysis of the C-terminal peptides of in vitro modified alpha-tubulin by MALDI-MS confirmed the covalent incorporation of nitrotyrosine into tubulin by TTL. In contrast to the C-terminal tyrosine, pancreatic carboxypeptidase A was incapable of cleaving nitrotyrosine from the modified alpha-tubulin.

L8 ANSWER 26 OF 39 MEDLINE on STN DUPLICATE .8  
ACCESSION NUMBER: 2001070000 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 11054573  
TITLE: Characterization of the human tubulin tyrosine ligase-like 1 gene (TTLL1) mapping to 22q13.1.  
AUTHOR: Trichet V; Ruault M; Roizes G; De Sario A  
CORPORATE SOURCE: Sequences Repetees et Centromeres Humains, CNRS UPR 1142, Institut de Biologie, 4, bv Henri IV, 34060, Montpellier, France.  
SOURCE: Gene, (2000 Oct 17) Vol. 257, No. 1, pp. 109-17.  
Journal code: 7706761. ISSN: 0378-1119.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AF104927; GENBANK-AF173935  
ENTRY MONTH: 200101  
ENTRY DATE: Entered STN: 20010322

Last Updated on STN: 20010322

Entered Medline: 20010104

AB This paper reports the characterization of the human tubulin tyrosine ligase-like 1 gene (TTL1), which maps to the chromosome region 22q13.1 and has been partially duplicated on three other acrocentric chromosomes: 13, 15 and 21. We describe the complete cDNA, TTL1a, coding for the putative 423 amino acid long TTL1 and alternative transcripts coding for truncated TTL1. Likely TTL1a corresponds to the 1.8 kb transcript that was detected in a wide range of tissues and has a stronger expression in heart, brain and testis. A 4.8 kb transcript was found only in brain tissues. We present an interspecies sequence comparison, revealing three conserved domains, named TTL1, TTL2 and TTL3, that are specific to the TTLs and TTL-like proteins.

L8 ANSWER 27 OF 39 MEDLINE on STN

ACCESSION NUMBER: 2000148025 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10685598

TITLE: Tubulin-tyrosine ligase, a long-lasting enigma.

AUTHOR: Erck C; Frank R; Wehland J

CORPORATE SOURCE: Abteilung Zellbiologie, Gesellschaft fuer Biotechnologische Forschung, Braunschweig, Germany.

SOURCE: Neurochemical research, (2000 Jan) Vol. 25, No. 1, pp. 5-10. Ref: 48

Journal code: 7613461. ISSN: 0364-3190.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200003

ENTRY DATE: Entered STN: 20000320

Last Updated on STN: 20000320

Entered Medline: 20000309

AB Tubulins and microtubules are subjected to several post-translational modifications of which the reversible detyrosination/tyrosination of the carboxy-terminal end of most alpha-tubulins has been extensively analysed. This modification cycle involves a specific carboxypeptidase and the activity of the tubulin-tyrosine ligase (TTL). The true physiological function of TTL has so far not been established. This review describes the purification of TTL to homogeneity by biochemical methods, its in vitro properties and the generation of monoclonal antibodies. These mabs not only enabled a very convenient and rapid purification of TTL by immunoaffinity chromatography but also its extensive characterization by protein sequencing, which led to the isolation of the full length cDNA. With this information, gene disruption should be feasible in order to determine the physiological significance of the tyrosination cycle.

L8 ANSWER 28 OF 39 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:434745 SCISEARCH

THE GENUINE ARTICLE: 321LD

TITLE: Phosphorylation of tubulin tyrosine ligase: A potential mechanism for regulation of alpha-tubulin tyrosination

AUTHOR: Idriss H T (Reprint)

CORPORATE SOURCE: Univ St Andrews, Sch Biomed Sci, N Haugh, St Andrews KY16 9ST, Fife, Scotland (Reprint); Univ St Andrews, Ctr Biomed Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA

COUNTRY OF AUTHOR: Scotland; USA

SOURCE: CELL MOTILITY AND THE CYTOSKELETON; (MAY 2000) Vol. 46, No. 1, pp. 1-5.

ISSN: 0886-1544.  
PUBLISHER: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW  
YORK, NY 10158-0012 USA.  
DOCUMENT TYPE: General Review; Journal  
LANGUAGE: English  
REFERENCE COUNT: 28  
ENTRY DATE: Entered STN: 2000  
Last Updated on STN: 2000

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB The tubulin tyrosination/detyrosination cycle is a well-established posttranslational modification, which is carried out by two enzymes: **Tubulin Tyrosine Ligase (TTL)** and **Tubulin Tyrosine Carboxypeptidase (TTCP)**. In this paper, I present evidence suggesting that the cycle itself is under the hierarchical control of reversible phosphorylation and that PKC mediated phosphorylation of TTL inhibits its activity, thereby preventing tubulin tyrosination. Phosphorylation of TTL is predicted to occur in a postulated Mg<sup>++</sup>/ATP binding fold, leading to inhibition of Mg<sup>++</sup>/ATP binding and TTL mediated catalysis. The implications of such control are also discussed. (C) 2000 Wiley-Liss, Inc.

L8 ANSWER 29 OF 39 MEDLINE on STN DUPLICATE 9  
ACCESSION NUMBER: 1998070560 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 9405300  
TITLE: Suppression of tubulin tyrosine  
ligase during tumor growth.  
AUTHOR: Lafanechere L; Courtay-Cahen C; Kawakami T; Jacrot M;  
Rudiger M; Wehland J; Job D; Margolis R L  
CORPORATE SOURCE: Laboratoire du Cytosquelette, INSERM U366, DBMS,  
Commisariat a l'Energie Atomique/Grenoble, Grenoble,  
France.  
SOURCE: Journal of cell science, (1998 Jan) Vol. 111 ( Pt 2), pp.  
171-81.  
Journal code: 0052457. ISSN: 0021-9533.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199803  
ENTRY DATE: Entered STN: 19980326  
Last Updated on STN: 19980326  
Entered Medline: 19980317

AB The C terminus of the tubulin alpha-subunit of most eukaryotic cells undergoes a cycle of tyrosination and detyrosination using two specific enzymes, a **tubulin tyrosine ligase (TTL)** and a **tubulin carboxypeptidase**. Although this enzyme cycle is conserved in evolution and exhibits rapid turnover, the meaning of this modification has remained elusive. We have isolated several NIH-3T3 derived clonal cell lines that lack TTL (TTL<sup>-</sup>). TTL<sup>-</sup> cells contain a unique tubulin isotype (delta2-tubulin) that can be detected with specific antibodies. When injected into nude mice, both TTL<sup>-</sup> cells and TTL<sup>+</sup> cells stably transfected with TTL cDNA form sarcomas. But in tumors formed from TTL rescued cells, TTL is systematically lost during tumor growth. A strong selection process has thus acted during tumor growth to suppress TTL activity. In accord with this result, we find suppression of TTL activity in the majority of human tumors assayed with delta2-tubulin antibody. We conclude there is a widespread loss of TTL activity during tumor growth in situ, suggesting that TTL activity may play a role in tumor cell regulation.

L8 ANSWER 30 OF 39 MEDLINE on STN DUPLICATE 10  
ACCESSION NUMBER: 97234553 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 9118990  
TITLE: Tubulin post-translational modifications--enzymes and their

mechanisms of action.

AUTHOR: MacRae T H

CORPORATE SOURCE: Department of Biology, Dalhousie University, Halifax, Canada.

SOURCE: European journal of biochemistry / FEBS, (1997 Mar 1) Vol. 244, No. 2, pp. 265-78. Ref: 172  
Journal code: 0107600. ISSN: 0014-2956.

PUB. COUNTRY: GERMANY: Germany, Federal Republic of

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199704

ENTRY DATE: Entered STN: 19970506  
Last Updated on STN: 20000303  
Entered Medline: 19970422

AB This review describes the enzymes responsible for the post-translational modifications of tubulin, including detyrosination/tyrosination, acetylation/deacetylation, phosphorylation, polyglutamylolation, polyglycylation and the generation of non-tyrosinatable alpha-tubulin. Tubulin tyrosine-ligase, which reattaches tyrosine to detyrosinated tubulin, has been extensively characterized and its gene sequenced. Enzymes such as tubulin-specific carboxypeptidase and alpha-tubulin acetyltransferase, required, respectively, for detyrosination and acetylation of tubulin, have yet to be purified to homogeneity and examined in defined systems. This has produced some conflicting results, especially for the carboxypeptidase. The phosphorylation of tubulin by several different types of kinases has been studied in detail but drawing conclusions is difficult because many of these enzymes modify proteins other than their actual substrates, an especially pertinent consideration for in vitro experiments. Tubulin phosphorylation in cultured neuronal cells has proven to be the best model for evaluation of kinase effects on tubulin/microtubule function. There is little information on the enzymes required for polyglutamylolation, polyglycylation, and production of non-tyrosinatable tubulin, but the available data permit interesting speculation of a mechanistic nature. Clearly, to achieve a full appreciation of tubulin post-translational changes the responsible enzymes must be characterized. Knowing when the enzymes are active in cells, if soluble or polymerized tubulin is the preferred substrate and the amino acid residues modified by each enzyme are all important. Moreover, acquisition of purified enzymes will lead to cloning and sequencing of their genes. With this information, one can manipulate cell genomes in order to either modify key enzymes or change their relative amounts, and perhaps reveal the physiological significance of tubulin post-translational modifications.

L8 ANSWER 31 OF 39 MEDLINE on STN DUPLICATE 11

ACCESSION NUMBER: 97261916 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9108330

TITLE: Tubulin tyrosine ligase:  
protein and mRNA expression in developing rat skeletal muscle.

AUTHOR: Arregui C O; Mas C R; Argarana C E; Barra H S

CORPORATE SOURCE: Centro de Investigaciones en Quimica Biologica de Cordoba (CIQUIBIC), UNC-CONICET, Dpto. de Quimica Biologica, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Argentina.

SOURCE: Development, growth & differentiation, (1997 Apr) Vol. 39, No. 2, pp. 167-78.  
Journal code: 0356504. ISSN: 0012-1592.

PUB. COUNTRY: Japan

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: GENBANK-U53214  
ENTRY MONTH: 199707  
ENTRY DATE: Entered STN: 19970805  
Last Updated on STN: 20020212  
Entered Medline: 19970724

AB Alpha tubulin can be post-translationally tyrosinated at the carboxy-terminus by a specific enzyme: tubulin tyrosine ligase. The expression of tubulin tyrosine ligase mRNA and protein during the development of rat skeletal muscle was examined in the present study. A portion of the coding region of the rat ligase cDNA was isolated and sequenced. The nucleotide and amino acid sequences showed about 90% homology with previously reported porcine and bovine ligase sequences. In newborn rats, ligase mRNA and protein were highly expressed in skeletal muscle. During early postnatal development, however, both ligase mRNA and protein dropped down dramatically. Quantitative measurements revealed that ligase protein at postnatal day 20 represented only 10% or less of the level at postnatal day 1. Ligase mRNA expression was also examined during the myogenesis in vitro. A strong ligase mRNA signal was detected in both undifferentiated myoblasts and cross-striated, contractile myotubes. The present results suggest that, during muscle differentiation, ligase function may be regulated by the amount of available mRNA. The discrepancy in the ligase expression between the in vivo and in vitro myogenesis suggests that factors controlling the levels of mRNA in vivo are lost in vitro.

L8 ANSWER 32 OF 39 MEDLINE on STN . DUPLICATE 12  
ACCESSION NUMBER: 93147125 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8093886  
TITLE: Characterization of the tubulin-tyrosine ligase.  
AUTHOR: Ersfeld K; Wehland J; Plessmann U; Dodemont H; Gerke V; Weber K  
CORPORATE SOURCE: Max-Planck-Institute for Biophysical Chemistry, Department of Biochemistry, Goettingen, Germany.  
SOURCE: The Journal of cell biology, (1993 Feb) Vol. 120, No. 3, pp. 725-32.  
Journal code: 0375356. ISSN: 0021-9525.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-X68453  
ENTRY MONTH: 199303  
ENTRY DATE: Entered STN: 19930312  
Last Updated on STN: 19980206  
Entered Medline: 19930302

AB The sequence of tubulin-tyrosine ligase (TTL), the enzyme catalyzing the ATP-dependent posttranslational addition of a tyrosine to the carboxyterminal end of detyrosinated alpha-tubulin, has been determined. TTL from bovine and porcine brain was purified by immunoaffinity chromatography and extensively characterized by protein sequencing. Oligonucleotides derived from the protein sequence were synthesized and partial cDNA sequences were obtained using reversed transcribed brain mRNA in polymerase chain reactions. Polymerase chain reaction fragments were used to isolate a full-length cDNA clone from a randomly primed lambda gt10 cDNA library obtained from embryonic porcine brain mRNA. Porcine TTL is encoded by 1,137 nucleotides corresponding to 379 amino acid residues. It has a molecular weight of 43,425 and a calculated isoelectric point of 6.51. Northern blot analysis revealed a surprisingly long mRNA (approximately 6 kb in embryonic porcine brain). The protein sequence of TTL shares no extended homology with the sequences in the data banks. TTL contains a potential serine phosphorylation site for cAMP-dependent protein kinase (RKAS at positions

73 to 76). Residues 244 to 258 lie at the surface of the molecule. A rabbit antibody raised against a synthetic peptide corresponding to this sequence binds to native TTL. The same sequence contains the cleavage site for endoprotease Glu-C (residue 248) previously shown to convert TTL into a nicked derivative in which the two fragments still form a tight complex but don't display enzymatic activity.

L8 ANSWER 33 OF 39 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1992:70844 SCISEARCH  
THE GENUINE ARTICLE: HA993  
TITLE: POLYGLUTAMYLATED ALPHA-TUBULIN CAN ENTER THE TYROSINATION  
DETYROSINATION CYCLE  
AUTHOR: EDDE B (Reprint); ROSSIER J; LECAER J P; PROME J C;  
DESBROYERES E; GROS F; DENOULET P  
CORPORATE SOURCE: COLL FRANCE, BIOCHIM CELLULAIRE LAB, 11 PL MARCELIN  
BERTHELOT, F-75231 PARIS 05, FRANCE (Reprint); CNRS, CTR  
RECH BIOCHIM & GENET CELLULAIRE, F-31062 TOULOUSE, FRANCE;  
CNRS, PHYSIOL NERVEUSE LAB, F-91198 GIF SUR YVETTE, FRANCE  
COUNTRY OF AUTHOR: FRANCE  
SOURCE: BIOCHEMISTRY, (21 JAN 1992) Vol. 31, No. 2, pp. 403-410.  
ISSN: 0006-2960.  
PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: LIFE  
LANGUAGE: English  
REFERENCE COUNT: 43  
ENTRY DATE: Entered STN: 1994  
Last Updated on STN: 1994

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB We have previously identified a major modification of neuronal alpha-tubulin which consists of the posttranslational addition of a varying number of glutamyl units on the gamma-carboxyl group of glutamate residue 445. This modification, called polyglutamylation, was initially found associated with detyrosinated alpha-tubulin [Edde, B., Rossier, J., Le Caer, J. P., Desbroyeres, E., Gros, F., & Denoulet, P. (1990) Science 247, 83-85]. In this report we show that a lateral chain of glutamyl units can also be present on tyrosinated alpha-tubulin. Incubation of cultured mouse brain neurons with radioactive tyrosine, in the presence of cycloheximide, resulted in a posttranslational labeling of six alpha-tubulin isoelectric variants. Because both tyrosination and polyglutamylation occur in the C-terminal region of alpha-tubulin, the structure of this region was investigated. [H-3]tyrosinated tubulin was mixed with a large excess of unlabeled mouse brain tubulin and digested with thermolysin. Five peptides, detected by their radioactivity, were purified by high-performance liquid chromatography. Amino acid sequencing and mass spectrometry showed that one of these peptides corresponds to the native C-terminal part of alpha-tubulin (VEGEGEEEGEEY)-V-440-Y-451 and that the remainders bear a varying number of glutamyl units linked to glutamate residue 445, which explains the observed heterogeneity of tyrosinated alpha-tubulin. A quantitative analysis showed that the different tyrosinated forms of alpha-tubulin represent a minor (13%) fraction of the total alpha-tubulin present in the brain and that most (80%) of these tyrosinated forms are polyglutamylated. The different forms of alpha-tubulin were found to be equal substrates for tubulin tyrosine ligase and tubulin carboxypeptidase, which indicates that alpha-tubulin can enter the tyrosination/detyrosination cycle independently of its degree of glutamylation.

L8 ANSWER 34 OF 39 MEDLINE on STN  
ACCESSION NUMBER: 89150728 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 3067795  
TITLE: Tubulin **expression** in trypanosomes..



AUTHOR: Gallo J M; Precigout E  
CORPORATE SOURCE: Laboratoire de Biologie Cellulaire, URA CNRS 80, UFR  
Sciences, Poitiers, France.  
SOURCE: Biology of the cell / under the auspices of the European  
Cell Biology Organization, (1988) Vol. 64, No. 2, pp.  
137-43. Ref: 46  
Journal code: 8108529. ISSN: 0248-4900.  
PUB. COUNTRY: France  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198904  
ENTRY DATE: Entered STN: 19900306  
Last Updated on STN: 19900306  
Entered Medline: 19890418

AB Microtubules in trypanosomes are the main component of the flagellar axoneme and of the subpellicular microtubule corset, whose relative positions determine the morphology of each cell stage of the life cycle of these parasites. Microtubules are polymers of tubulin, a protein dimer of two 55-kDa subunits, alpha- and beta-tubulin; in *Trypanosoma brucei*, the tubulin-coding sequences are clustered in a 40-kb fragment of tandemly repeated alpha- and beta-tubulin genes separated by a 170-bp intergenic zone. This cluster is transcribed in a unique RNA which is rapidly processed into mature mRNAs carrying the 5' 35-nucleotide leader sequence found in all trypanosome mRNAs. Although no heterogeneity has been found at the gene level, tubulin can be post-translationally modified in 2 ways: the C-terminal tyrosine of alpha-tubulin can be selectively cleaved and added again with 2 enzymes, tubulin carboxypeptidase and tubulin -tyrosine ligase; alpha-tubulin can also be acetylated on a lysine residue. Some molecular domains of tubulin are restricted to subpopulations of microtubules; for instance, the beta-tubulin form defined by the monoclonal antibody 1B41 is sequestered into a part of the subpellicular cytoskeleton limited to the flagellar adhesion zone, which might correspond to the group of 4 microtubules associated with a cisterna of the endoplasmic reticulum, forming the so-called "subpellicular microtubule quartet" (SFMQ). The early assembly of this zone in each daughter cell during the cell division of *T. brucei*, together with the alterations undergone by the domain defined by the monoclonal antitubulin 24E3 during the differentiation of *Trypanosoma cruzi*, suggest that specific tubulin forms are responsible for dynamic properties of SFMQ possibly involved in trypanosome morphogenesis.

L8 ANSWER 35 OF 39 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

ACCESSION NUMBER: 1987-09146 BIOTECHDS

TITLE: Tubulin-tyrosine-ligase has a  
binding site on beta-tubulin: a 2-domain structure of the  
enzyme;  
hybridoma construction for monoclonal antibody production

AUTHOR: Wehland J; Weber K  
CORPORATE SOURCE: Max-Planck-Inst.Biophys.Chem.  
LOCATION: Max Planck Institute for Biophysical Chemistry, D-3400  
Goettingen, Germany  
SOURCE: J.Cell Biol.; (1987) 104, 4, 1059-67  
CODEN: JCLBA3

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using 2 distinct tubulin-tyrosine-ligase  
monoclonal antibodies, several subunit-specific tubulin monoclonal  
antibodies, and chemical crosslinking, a ligase binding site was  
identified on beta-tubulin. For production of the enzyme specific  
antibodies, 6-wk-old female BALB/c mice were immunized 3 times at 3 wk  
intervals with 100-200 ug affinity purified ligase emulsified in Freund's  
complete adjuvant for the first injection and Freund's incomplete

adjuvant for the subsequent injections. The mice were tested for monoclonal antibody production, and spleen cells from the mouse with highest serum titer were fused with PAI myeloma cells. Positive producing hybridomas were cloned twice by limiting dilution and monoclonal antibodies produced in ascites fluid in BALB/c mice. The binding site characterized is retained when the carboxy-terminal domains of both tubulin subunits are removed by subtilisin treatment. This explains the extreme substrate specificity of the enzyme, which does not act on other cellular proteins or carboxy-terminal peptides derived from deetyrosinated alpha-tubulin. (42 ref)

L8 ANSWER 36 OF 39 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN  
ACCESSION NUMBER: 1985-04125 BIOTECHDS  
TITLE: Purification of brain tubulin-tyrosine-  
ligase by biochemical and immunological methods;  
monoclonal antibody preparation and hybridoma construction  
AUTHOR: Schroeder H C; Wehland J; Weber K  
CORPORATE SOURCE: Max-Planck-Inst.Biophys.Chem.  
LOCATION: Institute for Physiological Chemistry, University of Mainz,  
D-6500 Mainz, Germany.  
SOURCE: J.Cell Biol.; (1985) 100, 1, 276-81  
CODEN: JCLBA3  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Tubulin-tyrosin-ligase (TTL) was purified biochemically from pig brain tissue to near homogeneity (over 95%). The purified enzyme, (10-20 ug) was then injected 3 times into Balb/c mice at intervals of 3 weeks. Freund's complete adjuvant and incomplete adjuvant were used for the first and last 2 injections respectively. Immune spleen cells were fused with PAI myeloma cells, and hybridomas were selected in HAT. Those secreting monoclonal antibody to TTL were cloned twice in soft agar. The antibodies specifically recognized TTL in brain and liver tissue of various mammals. Purified ascites IgG were coupled to CNBr-activated Sepharose 4B. TTL from crude brain extract selectively bound to this immunoaffinity column in 1.5 M NaCl and eluted with 3 M NaCl. The purity of the eluted TTL was over 95%. It was a monomeric protein of apparent mol.weight 40,000. It associated as a 1/1 complex with alpha-beta-tubulin on gradient centrifugation. (32 ref)

L8 ANSWER 37 OF 39 MEDLINE on STN  
ACCESSION NUMBER: 84180758 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 6201294  
TITLE: Organization of microtubules in stabilized meristematic plant cells revealed by a rat monoclonal antibody reacting only with the tyrosinated form of alpha-tubulin.  
AUTHOR: Wehland J; Schroeder M; Weber K  
SOURCE: Cell biology international reports, (1984 Feb) Vol. 8, No. 2, pp. 147-50.  
Journal code: 7708050. ISSN: 0309-1651.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198406  
ENTRY DATE: Entered STN: 19900319  
Last Updated on STN: 19900319  
Entered Medline: 19840619

AB A rat monoclonal antibody against yeast tubulin (clone YL 1/2; Kilmartin et al., 1982) that reacts specifically with mammalian alpha-tubulin carrying a carboxyterminal tyrosine residue (Wehland et al., 1983) was used to localize microtubules in plant cells derived from onion root apices (Allium cepa L.). YL 1/2 reacted with all types of microtubular arrays known to occur in higher plant meristematic cells such as interphase cortical microtubules, pre-prophase bands, the mitotic

spindle and phragmoplast microtubules. The specific labeling of microtubules in isolated cells from onion root tips by YL 1/2 indicates that plant cells like animal cells contain tubulin tyrosine ligase, the enzyme which posttranslationally modifies alpha-tubulin. This enzyme could be involved in the dynamic regulation of microtubular arrays in all eukaryotic cells.

L8 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:81418 HCAPLUS

DOCUMENT NUMBER: 100:81418

TITLE: State of tyrosination of soluble synaptosomal tubulin

AUTHOR(S): Barra, Hector S.; Arce, Carlos A.

CORPORATE SOURCE: Fac. Cienc. Quim., UNC, Cordoba, 5016, Argent.

SOURCE: Comunicaciones Biologicas (1983), 2(1), 13-18

CODEN: COBIEJ; ISSN: 0326-1956

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The presence of tubulin-tyrosine ligase and the state of tyrosination of tubulin in the soluble synaptosomal fraction from rat brain was studied. The ligase was present in this soluble fraction and the amts. of tyrosinated and nontyrosinated tubulin (expressed as nmol/mg protein) were similar to those in the cytosolic fraction.

L8 ANSWER 39 OF 39 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 79099794 EMBASE

DOCUMENT NUMBER: 1979099794

TITLE: Studies on NGF induced differentiation in PC12 pheochromocytoma cells. Specific rise in tyrosyl tubulin ligase activity induced by the nerve growth factor.

AUTHOR: Levi A.; Castellani L.; Calissano P.; et al.

CORPORATE SOURCE: Lab. Biol. Cell., CNR, Roma, Italy

SOURCE: Bulletin of Molecular Biology and Medicine, (1978) Vol. 3, No. SUPPL. 1, pp. 42s-50s. .

CODEN: BMBMD5

COUNTRY: Italy

DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index

003 Endocrinology

029 Clinical Biochemistry

030 Pharmacology

LANGUAGE: English

AB A model system for the in vitro study of the mechanism of action of nerve growth factor (NGF) is described. The PC12 clonal line derived from a rat pheochromocytoma is shown to be very similar to the stem cell progenitor of both adrenal chromaffin cells and sympathetic neurones and to differentiate morphologically and physiologically like a nerve cell in response to NGF. Studies on tyrosyl tubulin ligase activity as a function of NGF induced differentiation in PC12 cells are reported.

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006

L1 7010 S TESTIS (W) SPECIFIC

L2 431 S TYROSINE (W) LIGASE?

L3 3 S L1 AND L2

L4 2 DUP REM L3 (1 DUPLICATE REMOVED)

L5 405 S TUBULIN (A) L2

L6 7556238 S CLON? OR EXPRESS? OR RECOMBINANT

L7 83 S L5 AND L6

L8 39 DUP REM L7 (44 DUPLICATES REMOVED)

=> s l8 and testis

L9 8 L8 AND TESTIS

=> d 1-8 ibib ab

L9 ANSWER 1 OF 8 MEDLINE on STN  
ACCESSION NUMBER: 2001070000 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 11054573  
TITLE: Characterization of the human tubulin  
tyrosine ligase-like 1 gene (TTLL1)  
mapping to 22q13.1.  
AUTHOR: Trichet V; Ruault M; Roizes G; De Sario A  
CORPORATE SOURCE: Sequences Repetees et Centromeres Humains, CNRS UPR 1142,  
Institut de Biologie, 4, bv Henri IV, 34060, Montpellier,  
France.  
SOURCE: Gene, (2000 Oct 17) Vol. 257, No. 1, pp. 109-17.  
Journal code: 7706761. ISSN: 0378-1119.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-AF104927; GENBANK-AF173935  
ENTRY MONTH: 200101  
ENTRY DATE: Entered STN: 20010322  
Last Updated on STN: 20010322  
Entered Medline: 20010104

AB This paper reports the characterization of the human tubulin  
tyrosine ligase-like 1 gene (TTLL1), which maps to the  
chromosome region 22q13.1 and has been partially duplicated on three other  
acrocentric chromosomes: 13, 15 and 21. We describe the complete cDNA,  
TTLL1a, coding for the putative 423 amino acid long TTLL1 and alternative  
transcripts coding for truncated TTLL1. Likely TTLL1a corresponds to the  
1.8 kb transcript that was detected in a wide range of tissues and has a  
stronger expression in heart, brain and testis. A 4.8  
kb transcript was found only in brain tissues. We present an interspecies  
sequence comparison, revealing three conserved domains, named TTLD1, TTLD2  
and TTLD3, that are specific to the TTLs and TTL-like proteins.

L9 ANSWER 2 OF 8 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN  
ACCESSION NUMBER: 2004-07314 BIOTECHDS  
TITLE: New testis-specific tubulin  
tyrosine-ligase-like BGS-42 polypeptide,  
useful for preventing, treating or ameliorating a medical  
condition, e.g. aberrant cellular proliferation, reproductive  
disorders or testicular disorders;  
involving vector-mediated gene transfer,  
expression in host cell for use in gene therapy  
AUTHOR: FEDER J N; WU S; NELSON T C  
PATENT ASSIGNEE: BRISTOL-MYERS SQUIBB CO  
PATENT INFO: WO 2004005487 15 Jan 2004  
APPLICATION INFO: WO 2003-US21605 9 Jul 2003  
PRIORITY INFO: US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: WPI: 2004-099381 [10]

AB DERWENT ABSTRACT:  
NOVELTY - A testis-specific tubulin tyrosine  
-ligase-like polypeptide, designated BGS-42 polypeptide, is  
new.  
DETAILED DESCRIPTION - A testis-specific tubulin  
tyrosine-ligase-like polypeptide, designated BGS-42  
polypeptide comprises or consists of: (a) a polypeptide fragment, domain,

epitope or the full-length protein of a fully defined sequence of 541 amino acids (I), as given in the specification, or the encoded sequence included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase activity; (b) a polypeptide comprising amino acids 2-541 of the sequence of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus the start methionine; (c) a polypeptide comprising amino acids 1-541 or 73-365 of the sequence of (I); or (d) a polypeptide comprising at least 424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

**WIDER DISCLOSURE** - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

**BIOTECHNOLOGY** - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the

presence or amount of **expression** of the polypeptide.

ACTIVITY - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene **expression**. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

L9 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:156681 HCAPLUS  
Correction of: 2005:60757

DOCUMENT NUMBER: 142:216629  
Correction of: 142:132329

TITLE: Gene **expression** profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin  
PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.  
CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 47

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

## PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-812777	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:156228 HCAPLUS  
Correction of: 2005:16967

DOCUMENT NUMBER: 142:192331  
Correction of: 142:108390

TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318

US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812782	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. **expression** of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:60755 HCAPLUS

Correction of: 2004:1036570

DOCUMENT NUMBER: 142:154259

Correction of: 142:36938

TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812707	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific



and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L9 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:60754 HCAPLUS  
Correction of: 2004:1036571

DOCUMENT NUMBER: 142:233342  
Correction of: 142:16836

TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005208519	A1	20050922	US 2004-989191	20041115
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812731	A 20040330
			WO 2004-US20836	A2 20040621

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L9 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1997 HCAPLUS

DOCUMENT NUMBER: 142:111841

TITLE: Gene expression profiles and biomarkers for the detection of depression-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812702	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular mental depression, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:722839 HCAPLUS

DOCUMENT NUMBER: 141:238811

TITLE: Protein and cDNA sequences of a novel human testis-specific tubulin tyrosine ligase like protein BGS-42, and diagnostic and therapeutic use

INVENTOR(S): Feder, John N.; Nelson, Thomas C.; Wu, Shujian; Krystek, Stanley R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 199 pp., Cont.-in-part of U.S. Ser. No. 615,659.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004171131	A1	20040902	US 2003-635977	20030807
US 2004157234	A1	20040812	US 2003-615659	20030709
PRIORITY APPLN. INFO.:			US 2002-394725P	P 20020709
			US 2003-615659	A2 20030709

AB The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

=> e feder j n/au

E1	106	FEDER J L/AU
E2	74	FEDER J M/AU
E3	185 -->	FEDER J N/AU
E4	1	FEDER J N */AU
E5	16	FEDER JACK B/AU
E6	1	FEDER JAN DAVID/AU
E7	1	FEDER JEAN M/AU
E8	3	FEDER JEAN MARC/AU
E9	60	FEDER JEFFREY L/AU
E10	88	FEDER JENS/AU
E11	1	FEDER JOHANN/AU
E12	2	FEDER JOHANN G/AU

=> s e3

L10 185 "FEDER J N"/AU

=> e wu s/au

E1	2	WU RUYU/AU
E2	1	WU RYH LIH/AU
E3	3568 -->	WU S/AU
E4	1	WU S */AU
E5	24	WU S A/AU
E6	86	WU S B/AU
E7	1667	WU S C/AU
E8	1	WU S C C/AU
E9	3	WU S C G/AU
E10	18	WU S C H/AU
E11	6	WU S C S/AU
E12	1	WU S C X P/AU

=> s e3

L11 3568 "WU S"/AU

=> e nelson t c/au

E1	6	NELSON T B/AU
E2	1	NELSON T BLAINE/AU
E3	130 -->	NELSON T C/AU
E4	99	NELSON T D/AU
E5	625	NELSON T E/AU
E6	35	NELSON T E JR/AU
E7	50	NELSON T F/AU

E8 1 NELSON T F JR/AU  
 E9 38 NELSON T G/AU  
 E10 55 NELSON T H/AU  
 E11 12 NELSON T HOLLAND/AU  
 E12 2 NELSON T I/AU

=> s e3

L12 130 "NELSON T C"/AU

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006

L1 7010 S TESTIS (W) SPECIFIC  
 L2 431 S TYROSINE (W)LIGASE?  
 L3 3 S L1 AND L2  
 L4 2 DUP REM L3 (1 DUPLICATE REMOVED)  
 L5 405 S TUBULIN (A) L2  
 L6 7556238 S CLON? OR EXPRESS? OR RECOMBINANT  
 L7 83 S L5 AND L6  
 L8 39 DUP REM L7 (44 DUPLICATES REMOVED)  
 L9 8 S L8 AND TESTIS  
 E FEDER J N/AU  
 L10 185 S E3  
 E WU S/AU  
 L11 3568 S E3  
 E NELSON T C/AU  
 L12 130 S E3

=> s l10 or l11 or l12

L13 3853 L10 OR L11 OR L12

=> s l2 and l13

L14 1 L2 AND L13

=> d all

L14 ANSWER 1 OF 1 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN  
 AN 2004-07314 BIOTECHDS  
 TI New testis-specific tubulin **tyrosine-ligase-like**  
 BGS-42 polypeptide, useful for preventing, treating or ameliorating a  
 medical condition, e.g. aberrant cellular proliferation, reproductive  
 disorders or testicular disorders;  
 involving vector-mediated gene transfer, expression in host cell for  
 use in gene therapy  
 AU FEDER J N; WU S; NELSON T C  
 PA BRISTOL-MYERS SQUIBB CO  
 PI WO 2004005487 15 Jan 2004  
 AI WO 2003-US21605 9 Jul 2003  
 PRAI US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002  
 DT Patent  
 LA English  
 OS WPI: 2004-099381 [10]  
 AB DERWENT ABSTRACT:  
 NOVELTY - A testis-specific tubulin **tyrosine-ligase**  
 -like polypeptide, designated BGS-42 polypeptide, is new.  
 DETAILED DESCRIPTION - A testis-specific tubulin **tyrosine-**  
**ligase-like** polypeptide, designated BGS-42 polypeptide comprises  
 or consists of: (a) a polypeptide fragment, domain, epitope or the  
 full-length protein of a fully defined sequence of 541 amino acids (I),  
 as given in the specification, or the encoded sequence included in ATCC  
 Deposit Number PTA-4454, having tyrosine tubulin ligase activity; (b) a

polypeptide comprising amino acids 2-541 of the sequence of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus the start methionine; (c) a polypeptide comprising amino acids 1-541 or 73-365 of the sequence of (I); or (d) a polypeptide comprising at least 424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

**WIDER DISCLOSURE** - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

**BIOTECHNOLOGY** - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

**ACTIVITY** - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic;

Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive;  
Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator;  
Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene expression. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

CC THERAPEUTICS, Protein Therapeutics; GENETIC TECHNIQUES and APPLICATIONS, Gene Expression Techniques and Analysis; DISEASE, Cancer; DISEASE, Central Nervous System; DISEASE, HIV and Other Virus Infections; DISEASE, Other Diseases; DIAGNOSTICS, Molecular Diagnostics; THERAPEUTICS, Gene Therapy

CT RECOMBINANT TESTIS-SPECIFIC TUBULIN TYROSINE-LIGASE  
-LIKE PROTEIN PREP., ISOL., VECTOR-MEDIATED GENE TRANSFER, EXPRESSION IN HOST CELL, APPL. CANCER, REPRODUCTIVE DISORDER, TESTICULAR DISORDER, PULMONARY DISORDER, GASTROINTESTINAL DISORDER, NEURAL DISORDER, IMMUNOLOGICAL DISORDER, ARTHRITIS, ASTHMA, AIDS, SEPSIS, ACNE DIAGNOSIS, THERAPY, GENE THERAPY PROTEIN TUMOR (23, 14)

=> d his

(FILE 'HOME' ENTERED AT 12:08:31 ON 28 FEB 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 12:09:07 ON 28 FEB 2006

L1 7010 S TESTIS (W) SPECIFIC  
L2 431 S TYROSINE (W) LIGASE?

L3 3 S L1 AND L2  
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)  
L5 405 S TUBULIN (A) L2  
L6 7556238 S CLON? OR EXPRESS? OR RECOMBINANT  
L7 83 S L5 AND L6  
L8 39 DUP REM L7 (44 DUPLICATES REMOVED)  
L9 8 S L8 AND TESTIS  
E FEDER J N/AU  
L10 185 S E3  
E WU S/AU  
L11 3568 S E3  
E NELSON T C/AU  
L12 130 S E3  
L13 3853 S L10 OR L11 OR L12  
L14 1 S L2 AND L13

V0/615,659

	L #	Hits	Search Text
1	L2	0	tytrosine adj ligase.ti.
2	L1	107	ligase.ti.
3	L3	606	testis adj specific
4	L4	2	tyrosine adj ligase?
5	L5	0	l3 same ligase?
6	L6	3261 1	ligase\$2
7	L7	8171 70	clon\$3 or express\$3 or recombinant
8	L8	1656 7	l6 same l7
9	L9	17	l3 same l8
10	L10	1697 34	FEDER WU NELSON
11	L11	58	l1 and l10



	Issue Date	Pages	Document ID	Title
1	20060202	74	US 2006002473 1 A1	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
2	20051222	119	US 2005028281 8 A1	Ubiquitin ligase inhibitors
3	20051201	35	US 2005026648 7 A1	High fidelity thermostable ligase and uses thereof
4	20051201	34	US 2005026643 9 A1	Thermostable RNA ligase from thermus phage
5	20051020	69	US 2005023332 0 A1	DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS
6	20050630	237	US 2005014254 3 A1	Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction
7	20050303	16	US 2005004921 4 A1	Inhibition of E3-ubiquitin ligase HAKAI for treatment of proliferative disorders
8	20050217	122	US 2005003734 6 A1	High fidelity detection of nucleic acid differences by ligase detection reaction
9	20041223	82	US 2004025914 1 A1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays

	Issue Date	Pages	Document ID	Title
10	20041216	70	US 2004025362 5 A1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
11	20041028	78	US 2004021422 4 A1	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
12	20041014	77	US 2004020306 1 A1	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
13	20040902	199	US 2004017113 1 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
14	20040812	171	US 2004015723 4 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
15	20040422	52	US 2004007697 3 A1	Antisense modulation of ubiquitin protein ligase expression
16	20030918	111	US 2003017575 0 A1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
17	20030515	260	US 2003009212 8 A1	Nucleic acid encoding RNA ligase of bacteriophage RM 378

18	20030501	262	US 2003008279 0 A1	RNA ligase of bacteriophage RM 378
----	----------	-----	--------------------------	---------------------------------------

	Issue Date	Page s	Document ID	Title
19	20030501	118	US 2003008254 5 A1	High fidelity detection of nucleic acid differences by ligase detection reaction
20	20030213	82	US 2003003201 6 A1	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
21	20030130	78	US 2003002218 2 A1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
22	20021017	70	US 2002015092 1 A1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
23	20020411	56	US 2002004208 3 A1	Ubiquitin ligase assay
24	20020228	44	US 2002002556 9 A1	COMPONENTS OF UBIQUITIN LIGASE COMPLEXES AND USES RELATED THERETO
25	20020221	25	US 2002002225 8 A1	Ubiquitin ligase
26	20050927	35	US 6949370 B1	High fidelity thermostable ligase and uses thereof
27	20050208	75	US 6852487 B1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
28	20041214	40	US 6831208 B1	4-coumarate co- enzyme a ligase promoter

29	20041116	253	US 6818425 B2	RNA ligase of bacteriophage RM 378
----	----------	-----	------------------	---------------------------------------

	Issue Date	Pages	Document ID	Title
30	20040928	77	US 6797470 B2	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
31	20040615	27	US 6750057 B2	Ubiquitin ligase
32	20040608	42	US 6747128 B2	Components of ubiquitin ligase complexes, and uses related thereto
33	20040525	46	US 6740495 B1	Ubiquitin ligase assay
34	20040518	55	US 6737244 B2	Ubiquitin ligase assay
35	20030610	107	US 6576453 B2	Thermostable DNA ligase mutants
36	20030114	103	US 6506594 B1	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
37	20020924	30	US 6455762 B1	Methods of modifying lignin in plants by transformation with a 4-coumarate coenzyme a ligase nucleic acid
38	20011106	114	US 6312892 B1	High fidelity detection of nucleic acid differences by ligase detection reaction
39	20010828	27	US 6280998 B1	Purified thermostable pyrococcus furiosus DNA ligase
40	20010731	77	US 6268148 B1	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions

	Issue Date	Pages	Document ID	Title
41	20010710	47	US 6258601 B1	Antisense modulation of ubiquitin protein ligase expression
42	20010403	28	US 6211161 B1	UDP-N-acetylmuramoyl-l-alanine:D-glutamate ligase (MURD) of staphylococcus aureus
43	20000425	50	US 6054564 A	Thermostable ligase mediated DNA amplification system for the detection of genetic diseases
44	20000222	77	US 6027889 A	Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
45	19991102	7	US 5976806 A	DNA ligase assay
46	19990727	20	US 5929045 A	Recombinant expression of polynucleotides encoding the UDP-N-acetylmuramoylalanine:D-glutamate ligase (MurD) of Streptococcus pneumoniae
47	19990608	25	US 5910408 A	Catalytic DNA having ligase activity
48	19981103	52	US 5830711 A	Thermostable ligase mediated DNA amplification system for the detection of genetic diseases
49	19980811	24	US 5792607 A	Method and kits for amplifying target nucleic acids applicable to both polymerase and ligase chain reactions

	Issue Date	Pages	Document ID	Title
50	19980609	25	US 5763256 A	Serine protease variants having peptide ligase activity
51	19980407	31	US 5736512 A	Serine protease variants having peptide ligase activity
52	19971223	27	US 5700672 A	Purified thermostable pyrococcus furiosus DNA ligase
53	19970513	33	US 5629173 A	Methods of use of serine protease variants having peptide ligase activity
54	19960702	30	US 5532146 A	Method for rendering ligase-based amplification products unamplifiable
55	19960409	32	US 5506137 A	Purified thermostable Pyrococcus furiosus DNA ligase
56	19960227	49	US 5494810 A	Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
57	19950404	27	US 5403737 A	Serine protease variants having peptide ligase activity
58	19870428	38	US 4661450 A	Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides



	Issue Date	Page s	Document ID	Title
1	20040902	199	US 2004017113 1 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42
2	20040812	171	US 2004015723 4 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42

	Issue Date	Pages	Document ID	Title
1	20051117	358	US 2005025511 4 A1	Methods and diagnosis for the treatment of preeclampsia
2	20050922	103	US 2005020850 0 A1	Signatures of ER status in breast cancer
3	20050818	212	US 2005018137 5 A1	Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
4	20050721	15	US 2005015875 6 A1	Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy
5	20040422	253	US 2004007695 5 A1	Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
6	20040325	135	US 2004005834 0 A1	Diagnosis and prognosis of breast cancer patients
7	20040226	259	US 2004003820 7 A1	Gene expression in bladder tumors
8	20040129	111	US 2004001851 3 A1	Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
9	20040108	165	US 2004000556 0 A1	Novel full-length cDNA
10	20040108	64	US 2004000555 9 A1	Markers of neuronal differentiation and morphogenesis

	Issue Date	Pages	Document ID	Title
11	20031211	206	US 20030228570 A1	Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
12	20031204	104	US 20030224374 A1	Diagnosis and prognosis of breast cancer patients
13	20021024	753	US 20020155119 A1	Isolation and use of fetal urogenital sinus expressed sequences
14	20020124	57	US 20020009730 A1	Human stress array
15	20051227	118	US 6979557 B2	Full-length cDNA
16	20040316	434	US 6706867 B1	DNA array sequence selection
17	20020101	227	US 6335170 B1	Gene expression in bladder tumors